Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATARAX vs ALAVERT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydroxyzine is a piperazine derivative with antihistaminic (H1-receptor antagonist) and anticholinergic properties; also exhibits sedative, anxiolytic, and antiemetic effects due to suppression of activity in subcortical areas of the CNS.
Loratadine is a selective inverse agonist of peripheral histamine H1 receptors, preventing histamine-mediated effects in allergic reactions.
Pruritus due to allergic conditions (FDA approved),Anxiety and tension (FDA approved for psychoneurosis),Sedation before and after general anesthesia (FDA approved),Off-label: Nausea and vomiting, motion sickness, insomnia
Seasonal allergic rhinitis,Perennial allergic rhinitis,Chronic idiopathic urticaria
25 mg orally 3-4 times daily; maximum 100 mg per day. Also available as 50 mg intramuscular injection every 4-6 hours.
10 mg orally once daily; for PRN use, 10 mg orally every 4-6 hours as needed, not to exceed 24 mg/day.
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly, hepatic impairment, or renal insufficiency (up to 30-40 hours); steady-state achieved within 3-4 days.
Terminal elimination half-life of loratadine is 8–11 hours; its active metabolite desloratadine has a half-life of 17–24 hours. The longer half-life of desloratadine contributes to sustained antihistaminic effect.
Primarily hepatic via CYP3A4 and CYP2D6; major metabolite is cetirizine.
Primarily metabolized by CYP3A4 and CYP2D6 to active metabolite descarboethoxyloratadine.
Primarily hepatic metabolism via CYP3A4 and CYP2D6; renal excretion of metabolites accounts for approximately 70-80% of the dose, with less than 1% excreted unchanged; fecal excretion is about 10-15%.
Approximately 40% of the dose is excreted in urine (25% as unchanged drug and 15% as active metabolite desloratadine) and 40% in feces (as metabolites).
Approximately 93% bound primarily to albumin and alpha-1-acid glycoprotein.
Loratadine: 97–99% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). Desloratadine: 82–87% bound.
Approximately 10-15 L/kg; large Vd indicates extensive tissue distribution, including penetration into the central nervous system.
Loratadine: approximately 120 L (1.7 L/kg for a 70 kg adult), indicating extensive tissue distribution. Desloratadine: 30–40 L/kg.
Oral bioavailability is approximately 100% (nearly complete absorption) with peak plasma concentrations at 2 hours; intramuscular bioavailability is similar to oral but with faster absorption.
Oral bioavailability is low (approximately 40–50%) due to extensive first-pass metabolism. Food increases bioavailability by 40% but does not affect clinical efficacy.
GFR 10-50 m L/min: administer every 24 hours. GFR <10 m L/min: contraindicated or reduce dose to 50% every 24 hours.
For GFR 30-50 m L/min: 10 mg every 48 hours. For GFR <30 m L/min or on dialysis: avoid use or adjust to 10 mg every 72 hours with close monitoring.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 50%. Class C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: 10 mg every 48 hours. Child-Pugh C: avoid use or 10 mg every 72 hours.
Children >6 years: 0.6 mg/kg orally every 6 hours; maximum 2 mg/kg/day. Children <6 years: 0.5 mg/kg orally every 4-6 hours; maximum 50 mg/day.
Age 6-11 years: 5 mg orally once daily; for PRN use, 5 mg every 4-6 hours, max 15 mg/day. Age ≥12 years: 10 mg orally once daily or 10 mg every 4-6 hours PRN, max 24 mg/day.
Initiate at 12.5 mg orally twice daily; may increase gradually. Avoid use in patients with significant renal impairment or dementia due to anticholinergic effects.
Initiate at 5 mg orally once daily; may increase to 10 mg once daily if tolerated and needed. Caution due to increased risk of anticholinergic effects and impaired renal function.
Not applicable; no black box warning.
None.
Drowsiness and impairment of alertness; avoid driving or operating machinery,Potentiation of CNS depressants (alcohol, barbiturates, opioids),Anticholinergic effects (urinary retention, blurred vision, constipation),QT prolongation risk (especially with electrolyte disturbances, pre-existing QT prolongation, or concurrent QT-prolonging drugs),Use with caution in elderly due to increased risk of sedation and falls,Tardive dyskinesia with prolonged high-dose use
Avoid use in patients with severe hepatic impairment,Renal impairment may require dose adjustment,Caution in elderly patients due to increased anticholinergic sensitivity
Hypersensitivity to hydroxyzine or any component of the formulation,Early pregnancy (first trimester) due to potential fetal harm,Porphyria,Lactation (excreted in breast milk)
Hypersensitivity to loratadine or any component of the formulation
No significant food interactions reported. However, alcohol should be avoided due to additive CNS depression. Grapefruit juice may theoretically increase hydroxyzine levels via CYP3A4 inhibition, but clinical significance is minimal; caution is advised.
Grapefruit juice may slightly increase loratadine absorption but not clinically significant. No specific dietary restrictions. Alcohol may increase CNS depression.
First trimester: Considered safe; large studies show no increased risk of major malformations. Second trimester: No known specific risks. Third trimester: Use near term may cause neonatal withdrawal or CNS depression (drowsiness, irritability, tremors) due to placental transfer.
ALAVERT (loratadine) is FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but no adequate, well-controlled studies in pregnant women. Based on available human data, first trimester exposure does not show increased risk of major malformations. Second and third trimester risks are not established, but adverse fetal outcomes are unlikely given lack of placental transfer concerns.
Atarax (hydroxyzine) is excreted into breast milk in small amounts; M/P ratio approximately 0.7. Use with caution; monitor infant for sedation, irritability, or feeding difficulties. The American Academy of Pediatrics considers it compatible with breastfeeding, but alternative agents may be preferred.
Loratadine is excreted into human breast milk. The milk-to-plasma ratio is approximately 1.17, with low relative infant dose (<2% of maternal weight-adjusted dose). Considered compatible with breastfeeding, but monitor infant for drowsiness or irritability. Caution in premature infants or those with renal impairment.
No dose adjustment is typically required for non-sedating use. However, pharmacokinetic changes in pregnancy (increased plasma volume, altered clearance) may necessitate cautious titration; start at lowest effective dose and adjust based on clinical response. For severe pruritus in pregnancy, typical adult dosing (25 mg tid or qid) is used, but monitor for excessive sedation.
No dose adjustment is routinely recommended for pregnancy. Pharmacokinetic changes during pregnancy (increased volume of distribution, hepatic metabolism) are not significant enough to require dose changes for loratadine. Standard adult dose (10 mg once daily) can be used.
ATARAX (hydroxyzine) is a first-generation antihistamine with anxiolytic and sedative properties. It is commonly used for pruritus, anxiety, and preoperative sedation. Note: QT prolongation risk at high doses; avoid in patients with known QT interval prolongation or concurrent use of other QT-prolonging agents. Onset of sedation is rapid, making it useful for sleep induction, but tolerance develops with chronic use. Anticholinergic effects (dry mouth, urinary retention) are dose-dependent.
Alavert (loratadine) is a non-sedating antihistamine with minimal anticholinergic effects. Onset of action is within 1-3 hours; peak effect at 8-12 hours. Useful for chronic urticaria and allergic rhinitis. Does not cause significant QTc prolongation. Avoid in severe hepatic impairment (Child-Pugh C) without dose adjustment.
Take exactly as prescribed; do not exceed recommended dose.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase drowsiness and dizziness.,Do not drive or operate heavy machinery until you know how this medication affects you.,Report any signs of allergic reaction (rash, difficulty breathing) or irregular heartbeat (palpitations, syncope) immediately.,Hydrate adequately to reduce dry mouth; sugar-free gum or candy can help.,Do not discontinue abruptly; follow your doctor's instructions for tapering if needed.
Take once daily at the same time, with or without food.,Do not exceed recommended dose to avoid side effects.,May cause mild drowsiness in some patients; avoid driving if affected.,Do not use for acute asthma attacks or lower respiratory symptoms.,Store at room temperature away from moisture and heat.,Notify your doctor if symptoms persist or worsen.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATARAX vs ALAVERT, answered by our medical review team.
ATARAX is a Antihistamine that works by Hydroxyzine is a piperazine derivative with antihistaminic (H1-receptor antagonist) and anticholinergic properties; also exhibits sedative, anxiolytic, and antiemetic effects due to suppression of activity in subcortical areas of the CNS.. ALAVERT is a Second-generation Antihistamine that works by Loratadine is a selective inverse agonist of peripheral histamine H1 receptors, preventing histamine-mediated effects in allergic reactions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATARAX and ALAVERT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATARAX is: 25 mg orally 3-4 times daily; maximum 100 mg per day. Also available as 50 mg intramuscular injection every 4-6 hours.. The standard adult dose of ALAVERT is: 10 mg orally once daily; for PRN use, 10 mg orally every 4-6 hours as needed, not to exceed 24 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATARAX and ALAVERT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATARAX is classified as Category C. First trimester: Considered safe; large studies show no increased risk of major malformations. Second trimester: No known specific risks. Third trimester: Use near term may cause n. ALAVERT is classified as Category C. ALAVERT (loratadine) is FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but no adequate, well-controlled studies in pregnant women. Based on ava. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.